Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6025235 | 0.78 | FBP1 (0.36) | HTR2CKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL6025233 | 0.78 | FBP1 (0.36) | HTR2CKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL22554261 | 0.77 | DDB1 (0.35) | DDB1CRBNKDM4EL3MBTL1NPC1 | |
| SCHEMBL21227272 | 0.77 | L3MBTL1 (0.39) | HTR2AHTR2CDDB1CRBNKDM4E | |
| SCHEMBL1092484 | 0.75 | HTR2A (0.68) | HTR2AHTR2CL3MBTL1MAPTLMNA | |
| SCHEMBL19960976 | 0.73 | DDB1 (0.33) | DDB1CRBNKDM4EL3MBTL1KMT2A | |
| SCHEMBL20080083 | 0.73 | GSK3B (0.34) | DDB1CRBNKDM4EL3MBTL1RAB9A | |
| SCHEMBL905853 | 0.69 | HTR2C (0.52) | HTR2AHTR2C | |
| SCHEMBL905855 | 0.69 | HTR2C (0.52) | HTR2AHTR2C | |
| SCHEMBL13448597 | 0.69 | PTGDR2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274711-B1 | NEW AZA-INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-6583134-B2 | Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1274711-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-15 | — | — | EP | disclosed |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | HOFFMANN-LA ROCHE INC. | 2001-09-27 | — | — | US | disclosed |
| WO-2001066548-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-13 | — | — | WO | disclosed |
| EP-1132389-A1 | New aza-indolyl derivatives for the treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | GPR119, GIPR, INMT | HTR2A 488/4885HTR2C 410/4885ERN1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.